COMMUNIQUÉS West-GlobeNewswire

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
08/08/2024
On-track for trem-cel + Mylotarg™ and VCAR33 ALLO clinical updates in the second half of 2024 CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering [...]
Sensus Healthcare Reports Second Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Second Quarter
08/08/2024
Revenues of $9.2 million compares with $4.5 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $2.1 million compares with negative $1.0 million a year ago “Fair Deal Agreement” recurring revenue [...]
Aligos Therapeutics Strengthens Board with Two New Independent Directors
08/08/2024
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to [...]
23andMe Reports First Quarter Fiscal 2025 Financial Results
08/08/2024
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter of fiscal [...]
Kura Oncology Reports Second Quarter 2024 Financial Results
08/08/2024
– Topline data from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025 – – Breakthrough Therapy Designation granted for ziftomenib in R/R NPM1-mutant AML – – Data from 100 patients [...]
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
08/08/2024
FOSTER CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]
Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results
08/08/2024
CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions [...]
Cytek Biosciences to Participate in Upcoming Investor Conferences
08/08/2024
FREMONT, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor [...]
Trevena Announces Reverse Stock Split
08/08/2024
CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system [...]
Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results
08/08/2024
Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplant IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: [...]
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
08/08/2024
Dosing initiated in healthy participants in Phase 1a/b trial for ABI-5366 targeting recurrent genital herpes, with interim Phase 1a first-in-human data expected in Q3 2024 and interim Phase 1b data in participants with [...]
Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates
08/08/2024
Continue to advance hypoimmune technology in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Enrolling patients in the GLEAM trial for SC291 in B-cell mediated [...]
Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
08/08/2024
Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy Received UK Clearance to Initiate Clinical Testing of TN-401 for PKP2- [...]
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
08/08/2024
- Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP inhibitors in high-grade [...]
scPharmaceuticals to Announce Second Quarter 2024 Financial Results on Wednesday, August 14, 2024
08/08/2024
Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and [...]
Hyperfine, Inc. Reports Record Quarterly Revenue and Raises FY 2024 Revenue Guidance
08/08/2024
─ Reports $3.6M in Q2 2024 Revenue; 50% Gross Margin ─ Raises FY 2024 Revenue Guidance to $13-16M GUILFORD, Conn., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology [...]
Seer Reports Second Quarter 2024 Financial Results
08/08/2024
Launched STAC in Europe and additional customer papers published in leading journals REDWOOD CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a [...]
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
08/08/2024
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune [...]
Iridex Reports Second Quarter 2024 Financial Results
08/08/2024
MOUNTAIN VIEW, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]

Pages